FDA
No application listedNo application naming BPC-157 or BPC 157 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDABPC-157: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is BPC-157?
BPC-157 is a synthetic 15-residue peptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, described in the literature as a partial sequence of body protection compound (BPC), isolated from human gastric juice. Published work is mostly rodent and cell-culture research. It is supplied here as a research material for laboratory use only.
What are the chemical facts for BPC-157?
- Name
- BPC-157
- Also written
- Body Protection Compound 157; PL 14736
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Length
- 15 residues
- Molecular formula
C62H98N16O22(matches the formula computed from the sequence)- Average molecular weight
- 1419.5 g/mol
- CAS number
137525-51-0(confirmed in PubChem)- PubChem
- CID 9941957
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of BPC-157?
- In cultured rat tendon cells BPC 157 was examined for effects on tendon outgrowth, cell survival and cell migration.[8]
- In tendon fibroblasts isolated from rat Achilles tendon the study measured growth hormone receptor expression.[7]
- In chorioallantoic membrane and endothelial tube-formation assays the study measured vessel formation, and VEGFR2 expression and activation.[6]
- A 2026 study reports an FBXO22 and BACH1 pathway in the pro-angiogenic mechanism, in endothelial cells and animal models.[2]
What has published research on BPC-157 looked at?
8 studies are cited for BPC-157. Each is labelled by design below, and each entry says what the paper measured.
- 3 review
- 2 in vitro and animal study
- 2 in vitro
- 1 systematic review
PubMed returns 226 records for the search terms published on the method page (50 of them with a review publication type, 0 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 4 registered studies whose intervention matches the name (4 interventional), checked 5 October 2026. Of the 226 BPC-157 records, 174 list an author named Sikiric P (PubMed author search, checked 5 October 2026).
- A 2025 narrative review evaluates the breadth and quality of the preclinical and clinical data on BPC-157 in musculoskeletal research, including its regulatory controversies.[3]
- A 2025 systematic review states that BPC-157 lacks US Food and Drug Administration approval and that its use is banned in professional sports.[4]
- A 2026 critical review evaluates the preclinical evidence in rodent ischaemia-reperfusion models, with attention to oxidative stress and endothelial nitric-oxide responses.[1]
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of BPC-157?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names BPC as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "BPC-157". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S0The WADA 2026 Prohibited List, in force 1 January 2026 names BPC-157 under S0 (non-approved substances). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for BPC-157?
[1] Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026;27.
Critical review of preclinical evidence for BPC 157 in rodent ischaemia-reperfusion models, with attention to oxidative stress and endothelial nitric-oxide responses.
[2] Zhang J, Liu M, Ou H, Wang Z, He L, Xiao Y, et al.. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Commun Signal. 2026;24.
Investigated the molecular mechanism of the pro-angiogenic effect of BPC157, reporting an FBXO22 and BACH1 pathway.
[3] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619.
Scoping review of BPC-157 mechanisms, preclinical and clinical data and safety concerns in musculoskeletal research, noting its regulatory status.
[4] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al.. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21:485-495.
Systematic review of BPC-157 reports in orthopaedic sports medicine.
[5] Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18.
Literature and patent review of preclinical reports on BPC 157.
[6] Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333.
Examined vessel formation in the chick chorioallantoic membrane and endothelial tube formation assays, and VEGFR2 expression and activation.
[7] Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-77.
Examined growth hormone receptor expression in tendon fibroblasts isolated from rat Achilles tendon.
[8] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110:774-80.
Examined tendon fibroblast outgrowth, survival and migration in cultured rat tendon cells exposed to BPC 157.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is BPC-157 covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.